Kathleen Ford Sells 1,813 Shares of Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology, Inc. (NASDAQ:KURA) COO Kathleen Ford sold 1,813 shares of the company’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total value of $15,337.98. Following the completion of the sale, the chief operating officer directly owned 153,560 shares of the company’s stock, valued at approximately $1,299,117.60. This trade represents a 1.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Kathleen Ford also recently made the following trade(s):

• On Friday, November 14th, Kathleen Ford sold 6,902 shares of Kura Oncology stock. The stock was sold at an average price of $11.18, for a total transaction of $77,164.36.

Kura Oncology Trading Down 1.2%

NASDAQ KURA traded down $0.10 during trading on Tuesday, reaching $8.47. 1,149,028 shares of the stock traded hands, compared to its average volume of 1,287,347. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $12.49. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 0.02. The firm has a market cap of $737.06 million, a price-to-earnings ratio of -3.42 and a beta of 0.25. The stock’s 50-day moving average price is $10.33 and its 200 day moving average price is $9.05.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%.The firm had revenue of $20.75 million for the quarter, compared to the consensus estimate of $17.48 million. Analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on KURA. Wedbush restated an “outperform” rating and issued a $38.00 price target (up from $36.00) on shares of Kura Oncology in a report on Friday, November 14th. Leerink Partners set a $20.00 target price on shares of Kura Oncology and gave the stock an “outperform” rating in a report on Tuesday, January 13th. JMP Securities reaffirmed a “market outperform” rating and issued a $24.00 price target on shares of Kura Oncology in a research note on Monday, October 20th. Zacks Research downgraded shares of Kura Oncology from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 20th. Finally, Barclays reaffirmed an “overweight” rating and issued a $28.00 price objective (up from $11.00) on shares of Kura Oncology in a research report on Monday, November 24th. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $28.00.

Institutional Trading of Kura Oncology

A number of institutional investors have recently made changes to their positions in KURA. Rhumbline Advisers boosted its holdings in Kura Oncology by 0.9% during the third quarter. Rhumbline Advisers now owns 119,935 shares of the company’s stock worth $1,061,000 after purchasing an additional 1,039 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in Kura Oncology by 9.5% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 20,993 shares of the company’s stock worth $217,000 after buying an additional 1,825 shares in the last quarter. Flower City Capital boosted its stake in shares of Kura Oncology by 20.0% during the 4th quarter. Flower City Capital now owns 12,000 shares of the company’s stock worth $125,000 after buying an additional 2,000 shares during the last quarter. Profund Advisors LLC boosted its stake in shares of Kura Oncology by 11.1% during the 3rd quarter. Profund Advisors LLC now owns 24,835 shares of the company’s stock worth $220,000 after buying an additional 2,478 shares during the last quarter. Finally, Arizona State Retirement System grew its holdings in shares of Kura Oncology by 15.8% in the 3rd quarter. Arizona State Retirement System now owns 20,481 shares of the company’s stock valued at $181,000 after acquiring an additional 2,802 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.